Navigation Links
StemCyte Locates East Coast Operations in New Jersey
Date:5/1/2008

Cell Therapy Company's Move Driven by Commitment of Governor and

Collaboration with Leading Stem Cell Researcher

EWING, N.J., May 1 /PRNewswire/ -- StemCyte Inc. today announced that it has located its East Coast operations in Ewing, N.J.

The move, which was supported by a Business Employment Incentive Program (BEIP) grant through the New Jersey Economic Development Authority, puts StemCyte's executives in close proximity to one of the company's collaborators: world-renowned spinal cord injury researcher Wise Young, M.D., Ph.D., at Rutgers University.

"The research being done by Dr. Young at Rutgers is top-notch," said Kenneth J. Giacin, chairman and chief executive officer of StemCyte. "In addition, Governor Corzine's plan for developing New Jersey as an active hub for stem cell research and therapeutics development was an important reason for our decision to move our East Coast operations to the state. We're pleased to become an integral part of New Jersey's life sciences community with our focus on therapies derived from umbilical cord blood."

In addition to the New Jersey location, StemCyte's operations are in California and Taiwan. The company is also developing StemCyte India Therapeutics in collaboration with Apollo Hospitals and Cadila Pharmaceuticals.

About StemCyte Inc.

StemCyte Inc. is a global cell therapy company with a focus on umbilical cord blood stem cells. Since 2001, the company's stem cell products have been used to successfully treat more than 600 patients suffering from life- threatening diseases and conditions. StemCyte also has a leadership position in the development of new cell therapies in high growth areas with the greatest clinical need. The company is accredited by AABB (formerly the American Association of Blood Banks) and Foundation for the Accreditation of Cellular Therapy (FACT). For more information, visit http://www.stemcyte.com.

StemCyte Media Contacts:

Russo Partners LLC

Ian Stone

(619) 814-3510

ian.stone@russopartnersllc.com

David Schull

(212) 845-4271

david.schull@russopartnersllc.com


'/>"/>
SOURCE StemCyte Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Millstone Medical Outsourcing Relocates Memphis Distribution Center Within 72 Hours of Tornado Disaster
2. Caliper Life Sciences Reports West Coast Consolidation of Operations
3. Phlo Affiliate to Launch AQUISS(TM) on East Coast
4. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
5. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
6. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. Biopure Operations Compliant With U.K. Manufacturing Guidelines
9. Genta Restructures Operations to Focus on Priority Initiatives
10. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
11. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):